SCHEMBL17792537

SCHEMBL17792537

CCn1[nH]c(=O)c(CNC(C)=O)c1C

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 1/20 0.35
▸ CYP1A2 P05177 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.32
▸ KDM4E B2RXH2 3/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ SETDB1 Q15047 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ KMT2A Q03164 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17789023 0.83 KDM4E (0.34) EZH2PTGDR2KDM4EALDH1A1HSD17B10
SCHEMBL17792574 0.82 CYP1A2 (0.30) CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL17792510 0.81 EZH2 (0.36) EZH2LMNA
SCHEMBL17792560 0.81 EZH2 (0.32) EZH2KDM4EALDH1A1HSD17B10LMNA
SCHEMBL17792509 0.80 CYP1A2 (0.34) EZH2CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL17792539 0.79 KMT2A (0.34) NPSR1MAPTKMT2A
SCHEMBL17792559 0.77 CYP1A2 (0.33) CYP1A2CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL17792512 0.77 DAO (0.47) EZH2ALDH1A1HSD17B10KMT2ASMN1; SMN2
SCHEMBL19391040 0.73 EZH2 (0.42) EZH2LMNASMN1; SMN2
SCHEMBL19391013 0.71 EZH2 (0.41) EZH2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170217941-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2017-08-03 — — US disclosed
US-9624205-B2 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. (US) 2017-04-18 — — US disclosed
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2016-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS EZH2 1501/4885CYP1A2 40/4885CYP3A4 19/4885
US-20170217941-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS BCOR, CYP2B6, AHR EZH2 1546/4885CYP1A2 56/4885CYP3A4 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback